Cipla recalls 5.8 lakh packets of gastric ulcer treatment drug from US market
The drug firm has manufactured the affected lot at its Kurkumbh facility in Maharashtra and then supplied to its New Jersey-based subsidiary
PTI | January 10, 2021 | Updated 14:07 IST
The USFDA cited cross-contamination with other products as the reason for the company recalling the product
Drug major Cipla is recalling over 5.8 lakh packets of a drug for the reduction in the occurrence of gastric ulcers from the US market, as per a report by the US Food and Drug Administration. The drug major is recalling esomeprazole magnesium for delayed-release oral suspension in unit dose packets in strengths 10 mg, 20 mg and 40 mg in the US market, the latest Enforcement Report by the USFDA said.